Tags

Type your tag names separated by a space and hit enter

Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives.
Brain Res. 2010 Mar 10; 1319:118-30.BR

Abstract

The concentration of plasma copper, ceruloplasmin (CRP), non-ceruloplasmin-bound Cu (NCBC), and metallothioneins (MTs) were studied as putative biomarkers for neurodegenerative diseases in patients and in their first-degree relatives. We found increased levels of Cu in the plasma of Alzheimer's disease (AD), Parkinson's disease (PD), and vascular dementia (VD) patients, and the increase observed in VD group was linked to the evolution of the disease. CRP was also elevated in response to the inflammatory component of the diseases, however, a correlation with illness progression was only observed in VD patients. The level of MTs is proportional to the evolution of VD. The Cu/CRP and Cu/MTs ratios are both indicative of disease progression for AD patients but not for those with PD or VD. Moreover, there is a correlation between the NCBC levels and the cognitive impairment estimated through the Mini-mental State Examination (MMSE) scale. This dependence is linear for AD and PD patients and non-linear for the VD ones. The relative values of NCBC showed dependence on the disease duration, especially for AD. Copper measurement and the Cu/CRP ratio may be predictive markers of risk for the first-degree relatives of AD patients. We believe that these results are valuable as a reliable clinical tool.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Arnal N
INIBIOLP (Instituto de Investigac]iones Bioquímicas de La Plata), CCT La Plata, CONICET-UNLP, Cátedra de Bioquímica y Biología Molecular, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, 60 y 120 (1900) La Plata, Argentina.
Cristalli DO
No affiliation info available
de Alaniz MJ
No affiliation info available
Marra CA
No affiliation info available

MeSH

AdultAgedAlzheimer DiseaseBiomarkersCeruloplasminCopperDementia, VascularDisease ProgressionFamilyFemaleHumansLinear ModelsMaleMetallothioneinMiddle AgedParkinson DiseaseRisk FactorsTime Factors

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20026314

Clinical Trial Links

Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease

Citation

Arnal, Nathalie, et al. "Clinical Utility of Copper, Ceruloplasmin, and Metallothionein Plasma Determinations in Human Neurodegenerative Patients and Their First-degree Relatives." Brain Research, vol. 1319, 2010, pp. 118-30.
Arnal N, Cristalli DO, de Alaniz MJ, et al. Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Res. 2010;1319:118-30.
Arnal, N., Cristalli, D. O., de Alaniz, M. J., & Marra, C. A. (2010). Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Research, 1319, 118-30. https://doi.org/10.1016/j.brainres.2009.11.085
Arnal N, et al. Clinical Utility of Copper, Ceruloplasmin, and Metallothionein Plasma Determinations in Human Neurodegenerative Patients and Their First-degree Relatives. Brain Res. 2010 Mar 10;1319:118-30. PubMed PMID: 20026314.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. AU - Arnal,Nathalie, AU - Cristalli,Diana Olga, AU - de Alaniz,María J T, AU - Marra,Carlos Alberto, Y1 - 2009/12/22/ PY - 2009/09/11/received PY - 2009/11/04/revised PY - 2009/11/08/accepted PY - 2009/12/23/entrez PY - 2009/12/23/pubmed PY - 2010/6/9/medline SP - 118 EP - 30 JF - Brain research JO - Brain Res VL - 1319 N2 - The concentration of plasma copper, ceruloplasmin (CRP), non-ceruloplasmin-bound Cu (NCBC), and metallothioneins (MTs) were studied as putative biomarkers for neurodegenerative diseases in patients and in their first-degree relatives. We found increased levels of Cu in the plasma of Alzheimer's disease (AD), Parkinson's disease (PD), and vascular dementia (VD) patients, and the increase observed in VD group was linked to the evolution of the disease. CRP was also elevated in response to the inflammatory component of the diseases, however, a correlation with illness progression was only observed in VD patients. The level of MTs is proportional to the evolution of VD. The Cu/CRP and Cu/MTs ratios are both indicative of disease progression for AD patients but not for those with PD or VD. Moreover, there is a correlation between the NCBC levels and the cognitive impairment estimated through the Mini-mental State Examination (MMSE) scale. This dependence is linear for AD and PD patients and non-linear for the VD ones. The relative values of NCBC showed dependence on the disease duration, especially for AD. Copper measurement and the Cu/CRP ratio may be predictive markers of risk for the first-degree relatives of AD patients. We believe that these results are valuable as a reliable clinical tool. SN - 1872-6240 UR - https://www.unboundmedicine.com/medline/citation/20026314/Clinical_utility_of_copper_ceruloplasmin_and_metallothionein_plasma_determinations_in_human_neurodegenerative_patients_and_their_first_degree_relatives_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-8993(09)02666-3 DB - PRIME DP - Unbound Medicine ER -